Advanced Blood-Brain Barrier Drug Delivery
Advanced Blood-Brain Barrier Drug Delivery is a reprint with a summary editorial, followed by 16 chapters that cover five areas of brain drug delivery, including receptor-mediated transport (RMT), carrier-mediated transport (CMT), active efflux transport (AET), Trojan horse lipid nanoparticles (LNP)...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 04925namaa2201405uu 4500 | ||
|---|---|---|---|
| 001 | doab96729 | ||
| 003 | oapen | ||
| 005 | 20230202 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 230202s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783036564166 | ||
| 020 | |a 9783036564173 | ||
| 020 | |a books978-3-0365-6416-6 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-6416-6 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MKG |2 bicssc | |
| 720 | 1 | |a Pardridge, William M. |4 edt | |
| 720 | 1 | |a Pardridge, William M. |4 oth | |
| 245 | 0 | 0 | |a Advanced Blood-Brain Barrier Drug Delivery |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 online resource (496 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a Advanced Blood-Brain Barrier Drug Delivery is a reprint with a summary editorial, followed by 16 chapters that cover five areas of brain drug delivery, including receptor-mediated transport (RMT), carrier-mediated transport (CMT), active efflux transport (AET), Trojan horse lipid nanoparticles (LNP), and in vivo methods for measurement of drug transport across the blood-brain barrier (BBB). | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine and Nursing |2 bicssc | |
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a 6-OHDA | ||
| 653 | |a agonist antibody | ||
| 653 | |a alpha-synuclein (αSYN) | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a amyotrophic lateral sclerosis (ALS) | ||
| 653 | |a antibody | ||
| 653 | |a ATP-binding cassette transporters | ||
| 653 | |a BBB-peptide shuttle | ||
| 653 | |a bispecific antibody | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a blood-brain barrier (BBB) | ||
| 653 | |a blood-brain barrier (BBB) | ||
| 653 | |a brain delivery | ||
| 653 | |a brain drug delivery | ||
| 653 | |a carrier-mediated transport | ||
| 653 | |a cavernous sinus | ||
| 653 | |a cell toxicity | ||
| 653 | |a chaperonin-containing TCP-1 | ||
| 653 | |a choline transporter-like protein-1 (CTL1) | ||
| 653 | |a compartmental models | ||
| 653 | |a decoy receptors | ||
| 653 | |a drug delivery | ||
| 653 | |a endosomal | ||
| 653 | |a endothelium | ||
| 653 | |a enzyme replacement therapy | ||
| 653 | |a fusion proteins | ||
| 653 | |a genetic engineering | ||
| 653 | |a hCMEC/D3 cells | ||
| 653 | |a IGF1R | ||
| 653 | |a IgG fusion proteins | ||
| 653 | |a immunotherapy | ||
| 653 | |a insulin receptor | ||
| 653 | |a ischemic stroke | ||
| 653 | |a large amino acid transporter 1 (LAT1) | ||
| 653 | |a lipid nanoparticle | ||
| 653 | |a liposome | ||
| 653 | |a liposomes | ||
| 653 | |a lysosomal storage disease | ||
| 653 | |a lysosomal storage disorders | ||
| 653 | |a molecular Trojan horse | ||
| 653 | |a monocarboxylate transporters (MCTs) | ||
| 653 | |a monoclonal antibody | ||
| 653 | |a mRNA transfection | ||
| 653 | |a n/a | ||
| 653 | |a nanoparticle | ||
| 653 | |a nanoparticles | ||
| 653 | |a neurodegeneration | ||
| 653 | |a neuronopathic mucopolysaccharidosis | ||
| 653 | |a neuroprotection | ||
| 653 | |a neurotensin | ||
| 653 | |a neurotrophic factors | ||
| 653 | |a NSC-34 cell lines | ||
| 653 | |a organic cation transporters (OCTNs) | ||
| 653 | |a Parkinson's disease | ||
| 653 | |a Parkinson's disease (PD) | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a photo-affinity labeling | ||
| 653 | |a physiologically based PK models | ||
| 653 | |a prodrugs | ||
| 653 | |a protein-based therapy | ||
| 653 | |a proteomics | ||
| 653 | |a proton-coupled organic cation antiporter | ||
| 653 | |a receptor-mediated transcytosis | ||
| 653 | |a receptor-mediated transcytosis (RMT) | ||
| 653 | |a receptor-mediated transport | ||
| 653 | |a single domains antibody | ||
| 653 | |a SLC transporters | ||
| 653 | |a solute carrier (SLC) transporters | ||
| 653 | |a solute carriers (SLCs) | ||
| 653 | |a ssPalm | ||
| 653 | |a SWATH-MS | ||
| 653 | |a SWATH-MS (sequential window acquisition of all theoretical-mass spectra) | ||
| 653 | |a targeting | ||
| 653 | |a taurine transporter (Taut) | ||
| 653 | |a TNF-α inhibitor | ||
| 653 | |a transferrin | ||
| 653 | |a transferrin receptor | ||
| 653 | |a transferrin receptor (TfR) | ||
| 653 | |a transferrin receptor 1 (TfR1) | ||
| 653 | |a translation | ||
| 653 | |a TrkB | ||
| 653 | |a variable new antigen receptor (VNAR) | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/96729 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/6675 |7 0 |z Open Access: DOAB, download the publication |